The influenza A virus is a critical public health problem that causes epidemics and pandemics, and occurs widely all over the world. Various
vaccines against the virus have not provided a
solution to the problem. Different approaches, particularly M2e
peptide-based
vaccines, are available for developing universal
vaccines against
influenza A. However, it is important to select a suitable carrier to obtain an effective
vaccine. Accordingly, studies on the usage of various carriers are ongoing. Particularly,
polymer-based carriers have gained importance due to both
drug delivery and adjuvant effects. Therefore, bioconjugate of the M2e
protein peptide from the influenza A virus covalent bonded with
poly(acrylic) acid was synthesized in our study for the first time. The characterization was performed using size-exclusion chromatography and fluorescence spectroscopy; subsequently, it was found that the bioconjugate of the examined lower doses (0.05 and 0.5 mg/ml) have no toxic effects on human cell lines. These results suggest that, in the future, the
poly(acrylic) acid bioconjugate of the M2e
peptide should be studied in vivo for universal
vaccine development against the influenza A virus.